Drug Evaluations

"Rifabutin In Therapy of HIV-1 Associated Pulmonary Tuberculosis, Indication of Earlier Sputum Conversion in a Single Blinded, Randomized Comparative Pilot Study in Uganda."

Published in TB and Outbreaks Week, September 11th, 1995

According to an abstract submitted by the authors to the 19th International Congress of Chemotherapy, held July 16-21, 1995, in Montreal, Quebec, Canada, "Introduction: Tuberculosis is the most frequently diagnosed HIV-1 associated opportunistic infection worldwide and a major health problem in Uganda. Objective: Evaluation of feasibility of a larger comparative phase III trial with rifabutin as a substitute for rifabutin in treatment of HIV-1 associated pulmonary tuberculosis (PTB) Design: Single-blinded randomized study in 50 HIV+ patients with PTB at Joint Clinical Research Centre in Kampala/Uganda. Comparison of six months short course regimens with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1995-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry